ID SNPC4_HUMAN Reviewed; 1469 AA. AC Q5SXM2; Q9Y6P7; DT 25-OCT-2005, integrated into UniProtKB/Swiss-Prot. DT 21-DEC-2004, sequence version 1. DT 02-OCT-2024, entry version 173. DE RecName: Full=snRNA-activating protein complex subunit 4; DE Short=SNAPc subunit 4; DE AltName: Full=Proximal sequence element-binding transcription factor subunit alpha; DE Short=PSE-binding factor subunit alpha; DE Short=PTF subunit alpha; DE AltName: Full=snRNA-activating protein complex 190 kDa subunit; DE Short=SNAPc 190 kDa subunit; GN Name=SNAPC4 {ECO:0000312|EMBL:CAI13935.1, ECO:0000312|HGNC:HGNC:11137}; GN Synonyms=SNAP190 {ECO:0000312|EMBL:AAC02972.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAC02972.1} RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND INTERACTION WITH SNAPC2. RC TISSUE=Teratocarcinoma {ECO:0000312|EMBL:AAC02972.1}; RX PubMed=9418884; DOI=10.1128/mcb.18.1.368; RA Wong M.W., Henry R.W., Ma B., Kobayashi R., Klages N., Matthias P., RA Strubin M., Hernandez N.; RT "The large subunit of basal transcription factor SNAPc is a Myb domain RT protein that interacts with Oct-1."; RL Mol. Cell. Biol. 18:368-377(1998). RN [2] {ECO:0000312|EMBL:CAI13935.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [3] {ECO:0000305} RP INTERACTION WITH SNAPC1; SNAPC2 AND SNAPC5, AND MUTAGENESIS OF GLN-94; RP GLN-115; LEU-1314; LEU-1355; LEU-1362; LEU-1364 AND LEU-1369. RX PubMed=11056176; DOI=10.1074/jbc.m009301200; RA Ma B., Hernandez N.; RT "A map of protein-protein contacts within the small nuclear RNA-activating RT protein complex SNAPc."; RL J. Biol. Chem. 276:5027-5035(2001). RN [4] {ECO:0000305} RP FUNCTION, AND INTERACTION WITH TBP AND BRF2. RX PubMed=12621023; DOI=10.1074/jbc.m204247200; RA Hinkley C.S., Hirsch H.A., Gu L., LaMere B., Henry R.W.; RT "The small nuclear RNA-activating protein 190 Myb DNA binding domain RT stimulates TATA box-binding protein-TATA box recognition."; RL J. Biol. Chem. 278:18649-18657(2003). RN [5] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1157, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1398 AND SER-1400, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-68, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-68; SER-599; SER-626 AND RP SER-1224, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [11] RP VARIANTS NEDRSO GLU-185; ASN-199; ARG-386; ASN-441; THR-479; RP 810-ARG--VAL-1469 DEL AND VAL-967, AND INVOLVEMENT IN NEDRSO. RX PubMed=36965478; DOI=10.1016/j.ajhg.2023.03.001; RG Undiagnosed Diseases Network; RA Frost F.G., Morimoto M., Sharma P., Ruaud L., Belnap N., Calame D.G., RA Uchiyama Y., Matsumoto N., Oud M.M., Ferreira E.A., Narayanan V., RA Rangasamy S., Huentelman M., Emrick L.T., Sato-Shirai I., Kumada S., RA Wolf N.I., Steinbach P.J., Huang Y., Pusey B.N., Passemard S., Levy J., RA Drunat S., Vincent M., Guet A., Agolini E., Novelli A., Digilio M.C., RA Rosenfeld J.A., Murphy J.L., Lupski J.R., Vezina G., Macnamara E.F., RA Adams D.R., Acosta M.T., Tifft C.J., Gahl W.A., Malicdan M.C.V.; RT "Bi-allelic SNAPC4 variants dysregulate global alternative splicing and RT lead to neuroregression and progressive spastic paraparesis."; RL Am. J. Hum. Genet. 110:663-680(2023). CC -!- FUNCTION: Part of the SNAPc complex required for the transcription of CC both RNA polymerase II and III small-nuclear RNA genes. Binds to the CC proximal sequence element (PSE), a non-TATA-box basal promoter element CC common to these 2 types of genes. Recruits TBP and BRF2 to the U6 snRNA CC TATA box. {ECO:0000269|PubMed:12621023, ECO:0000269|PubMed:9418884}. CC -!- SUBUNIT: Part of the SNAPc complex composed of 5 subunits: SNAPC1, CC SNAPC2, SNAPC3, SNAPC4 and SNAPC5. SNAPC4 interacts with SNAPC1, CC SNAPC2, SNAPC5, BRF2 and TBP. {ECO:0000269|PubMed:11056176, CC ECO:0000269|PubMed:12621023, ECO:0000269|PubMed:9418884}. CC -!- INTERACTION: CC Q5SXM2; Q16533: SNAPC1; NbExp=12; IntAct=EBI-2801093, EBI-11915024; CC Q5SXM2; O75971: SNAPC5; NbExp=3; IntAct=EBI-2801093, EBI-749483; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00625}. CC -!- DISEASE: Neurodevelopmental disorder with motor regression, progressive CC spastic paraplegia, and oromotor dysfunction (NEDRSO) [MIM:620515]: An CC autosomal recessive disorder characterized by delayed motor development CC and developmental regression after the first year of life, followed by CC progressive spasticity with gait alterations, paraparesis, and oromotor CC dysfunction. Most individuals have cerebral, cerebellar, or basal CC ganglia volume loss. {ECO:0000269|PubMed:36965478}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF032387; AAC02972.1; -; mRNA. DR EMBL; AL592301; CAI13935.1; -; Genomic_DNA. DR CCDS; CCDS6998.1; -. DR PIR; T09219; T09219. DR RefSeq; NP_003077.2; NM_003086.3. DR RefSeq; XP_005266153.1; XM_005266096.2. DR RefSeq; XP_006717304.1; XM_006717241.2. DR RefSeq; XP_006717305.1; XM_006717242.3. DR PDB; 7XUR; EM; 3.49 A; A=1-505. DR PDB; 7ZWC; EM; 3.20 A; c=1-1469. DR PDB; 7ZWD; EM; 3.00 A; c=1-1469. DR PDB; 7ZX7; EM; 3.40 A; c=1-1469. DR PDB; 7ZX8; EM; 3.00 A; c=1-1469. DR PDB; 7ZXE; EM; 3.50 A; c=1-1469. DR PDB; 8ITY; EM; 3.90 A; 4=1-1469. DR PDB; 8IUE; EM; 4.10 A; 4=1-1469. DR PDB; 8IUH; EM; 3.40 A; 4=1-1469. DR PDBsum; 7XUR; -. DR PDBsum; 7ZWC; -. DR PDBsum; 7ZWD; -. DR PDBsum; 7ZX7; -. DR PDBsum; 7ZX8; -. DR PDBsum; 7ZXE; -. DR PDBsum; 8ITY; -. DR PDBsum; 8IUE; -. DR PDBsum; 8IUH; -. DR AlphaFoldDB; Q5SXM2; -. DR EMDB; EMD-14996; -. DR EMDB; EMD-14997; -. DR EMDB; EMD-15006; -. DR EMDB; EMD-15007; -. DR EMDB; EMD-15009; -. DR EMDB; EMD-33477; -. DR EMDB; EMD-35712; -. DR EMDB; EMD-35719; -. DR EMDB; EMD-35722; -. DR SMR; Q5SXM2; -. DR BioGRID; 112505; 78. DR ComplexPortal; CPX-8637; SNAPc snRNA activating protein complex. DR CORUM; Q5SXM2; -. DR IntAct; Q5SXM2; 77. DR MINT; Q5SXM2; -. DR STRING; 9606.ENSP00000298532; -. DR GlyGen; Q5SXM2; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q5SXM2; -. DR PhosphoSitePlus; Q5SXM2; -. DR BioMuta; SNAPC4; -. DR DMDM; 74762223; -. DR jPOST; Q5SXM2; -. DR MassIVE; Q5SXM2; -. DR PaxDb; 9606-ENSP00000298532; -. DR PeptideAtlas; Q5SXM2; -. DR ProteomicsDB; 63996; -. DR Pumba; Q5SXM2; -. DR Antibodypedia; 18701; 199 antibodies from 21 providers. DR DNASU; 6621; -. DR Ensembl; ENST00000298532.2; ENSP00000298532.2; ENSG00000165684.6. DR Ensembl; ENST00000637388.2; ENSP00000490037.2; ENSG00000165684.6. DR Ensembl; ENST00000684778.1; ENSP00000510559.1; ENSG00000165684.6. DR GeneID; 6621; -. DR KEGG; hsa:6621; -. DR MANE-Select; ENST00000684778.1; ENSP00000510559.1; NM_003086.4; NP_003077.2. DR UCSC; uc004chh.4; human. DR AGR; HGNC:11137; -. DR CTD; 6621; -. DR DisGeNET; 6621; -. DR GeneCards; SNAPC4; -. DR HGNC; HGNC:11137; SNAPC4. DR HPA; ENSG00000165684; Low tissue specificity. DR MalaCards; SNAPC4; -. DR MIM; 602777; gene. DR MIM; 620515; phenotype. DR neXtProt; NX_Q5SXM2; -. DR OpenTargets; ENSG00000165684; -. DR PharmGKB; PA35985; -. DR VEuPathDB; HostDB:ENSG00000165684; -. DR eggNOG; KOG0049; Eukaryota. DR GeneTree; ENSGT00940000160404; -. DR HOGENOM; CLU_004641_0_0_1; -. DR InParanoid; Q5SXM2; -. DR OMA; MAFHQTK; -. DR OrthoDB; 1709448at2759; -. DR PhylomeDB; Q5SXM2; -. DR TreeFam; TF313064; -. DR PathwayCommons; Q5SXM2; -. DR Reactome; R-HSA-6807505; RNA polymerase II transcribes snRNA genes. DR Reactome; R-HSA-749476; RNA Polymerase III Abortive And Retractive Initiation. DR Reactome; R-HSA-76071; RNA Polymerase III Transcription Initiation From Type 3 Promoter. DR SignaLink; Q5SXM2; -. DR BioGRID-ORCS; 6621; 736 hits in 1178 CRISPR screens. DR ChiTaRS; SNAPC4; human. DR GeneWiki; SNAPC4; -. DR GenomeRNAi; 6621; -. DR Pharos; Q5SXM2; Tbio. DR PRO; PR:Q5SXM2; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q5SXM2; protein. DR Bgee; ENSG00000165684; Expressed in sural nerve and 163 other cell types or tissues. DR ExpressionAtlas; Q5SXM2; baseline and differential. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; TAS:ProtInc. DR GO; GO:0019185; C:snRNA-activating protein complex; IDA:UniProtKB. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0016251; F:RNA polymerase II general transcription initiation factor activity; IDA:ARUK-UCL. DR GO; GO:0000995; F:RNA polymerase III general transcription initiation factor activity; IDA:ARUK-UCL. DR GO; GO:0001006; F:RNA polymerase III type 3 promoter sequence-specific DNA binding; IBA:GO_Central. DR GO; GO:0042795; P:snRNA transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0042796; P:snRNA transcription by RNA polymerase III; IDA:UniProtKB. DR CDD; cd00167; SANT; 2. DR Gene3D; 1.10.10.60; Homeodomain-like; 4. DR InterPro; IPR009057; Homeodomain-like_sf. DR InterPro; IPR051575; Myb-like_DNA-bd. DR InterPro; IPR017930; Myb_dom. DR InterPro; IPR001005; SANT/Myb. DR InterPro; IPR017884; SANT_dom. DR PANTHER; PTHR46621; SNRNA-ACTIVATING PROTEIN COMPLEX SUBUNIT 4; 1. DR PANTHER; PTHR46621:SF1; SNRNA-ACTIVATING PROTEIN COMPLEX SUBUNIT 4; 1. DR Pfam; PF13921; Myb_DNA-bind_6; 2. DR SMART; SM00717; SANT; 5. DR SUPFAM; SSF46689; Homeodomain-like; 3. DR PROSITE; PS51294; HTH_MYB; 3. DR PROSITE; PS50090; MYB_LIKE; 2. PE 1: Evidence at protein level; KW 3D-structure; Disease variant; DNA-binding; Intellectual disability; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome; KW Repeat; Transcription; Transcription regulation. FT CHAIN 1..1469 FT /note="snRNA-activating protein complex subunit 4" FT /id="PRO_0000197120" FT DOMAIN 250..288 FT /note="Myb-like 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00133" FT DOMAIN 289..343 FT /note="HTH myb-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00625" FT DOMAIN 344..395 FT /note="Myb-like 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00133" FT DOMAIN 396..451 FT /note="HTH myb-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00625" FT DOMAIN 452..503 FT /note="HTH myb-type 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00625" FT DNA_BIND 317..341 FT /note="H-T-H motif" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00625" FT DNA_BIND 424..447 FT /note="H-T-H motif" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00625" FT DNA_BIND 476..499 FT /note="H-T-H motif" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00625" FT REGION 16..82 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 84..133 FT /note="SNAPC5-binding" FT /evidence="ECO:0000269|PubMed:11056176" FT REGION 501..558 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 577..661 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 685..710 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 834..894 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 932..981 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1001..1051 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1121..1167 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1184..1266 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1281..1393 FT /note="SNAPC2-binding" FT /evidence="ECO:0000269|PubMed:11056176" FT REGION 1430..1449 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 28..42 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 57..82 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 501..516 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 517..546 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 600..623 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 834..881 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 967..981 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1018..1032 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1126..1140 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1430..1446 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 68 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 599 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 626 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1157 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18220336" FT MOD_RES 1224 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1398 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 1400 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 1440 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BP86" FT VARIANT 44 FT /note="D -> N (in dbSNP:rs7031489)" FT /id="VAR_059455" FT VARIANT 185 FT /note="K -> E (in NEDRSO; uncertain significance)" FT /evidence="ECO:0000269|PubMed:36965478" FT /id="VAR_089014" FT VARIANT 199 FT /note="D -> N (in NEDRSO; uncertain significance)" FT /evidence="ECO:0000269|PubMed:36965478" FT /id="VAR_089015" FT VARIANT 386 FT /note="Q -> R (in NEDRSO; uncertain significance)" FT /evidence="ECO:0000269|PubMed:36965478" FT /id="VAR_089016" FT VARIANT 441 FT /note="D -> N (in NEDRSO; uncertain significance)" FT /evidence="ECO:0000269|PubMed:36965478" FT /id="VAR_089017" FT VARIANT 479 FT /note="I -> T (in NEDRSO; uncertain significance)" FT /evidence="ECO:0000269|PubMed:36965478" FT /id="VAR_089018" FT VARIANT 799 FT /note="H -> Q (in dbSNP:rs3812571)" FT /id="VAR_050193" FT VARIANT 810..1469 FT /note="Missing (in NEDRSO; likely pathogenic)" FT /evidence="ECO:0000269|PubMed:36965478" FT /id="VAR_089019" FT VARIANT 967 FT /note="G -> V (in NEDRSO; uncertain significance)" FT /evidence="ECO:0000269|PubMed:36965478" FT /id="VAR_089020" FT VARIANT 1448 FT /note="P -> S (in dbSNP:rs3812561)" FT /id="VAR_050194" FT MUTAGEN 94 FT /note="Q->A: Abolishes SNAPC5 binding in the absence of FT SNAPC1. Minimal effect on SNAPC5 binding in the presence of FT SNAPC1." FT /evidence="ECO:0000269|PubMed:11056176" FT MUTAGEN 94 FT /note="Q->L: Abolishes SNAPC5 binding in the absence of FT SNAPC1. Minimal effect on SNAPC5 binding in the presence of FT SNAPC1." FT /evidence="ECO:0000269|PubMed:11056176" FT MUTAGEN 115 FT /note="Q->L: Abolishes SNAPC5 binding in the absence of FT SNAPC1. Minimal effect on SNAPC5 binding in the presence of FT SNAPC1." FT /evidence="ECO:0000269|PubMed:11056176" FT MUTAGEN 1314 FT /note="L->A: Abolishes SNAPC2-binding." FT /evidence="ECO:0000269|PubMed:11056176" FT MUTAGEN 1355 FT /note="L->A: Abolishes SNAPC2-binding." FT /evidence="ECO:0000269|PubMed:11056176" FT MUTAGEN 1362 FT /note="L->A: Abolishes SNAPC2-binding." FT /evidence="ECO:0000269|PubMed:11056176" FT MUTAGEN 1364 FT /note="L->A: Abolishes SNAPC2-binding." FT /evidence="ECO:0000269|PubMed:11056176" FT MUTAGEN 1369 FT /note="L->A: Decreased binding to SNAPC2." FT /evidence="ECO:0000269|PubMed:11056176" FT CONFLICT 1046 FT /note="A -> G (in Ref. 1; AAC02972)" FT /evidence="ECO:0000305" FT HELIX 83..122 FT /evidence="ECO:0007829|PDB:7ZWC" FT HELIX 142..144 FT /evidence="ECO:0007829|PDB:7ZWC" FT STRAND 146..149 FT /evidence="ECO:0007829|PDB:7XUR" FT STRAND 153..155 FT /evidence="ECO:0007829|PDB:7ZWC" FT STRAND 156..158 FT /evidence="ECO:0007829|PDB:8IUH" FT HELIX 163..170 FT /evidence="ECO:0007829|PDB:7ZWC" FT TURN 176..178 FT /evidence="ECO:0007829|PDB:7ZWC" FT HELIX 186..220 FT /evidence="ECO:0007829|PDB:7ZWC" FT HELIX 226..246 FT /evidence="ECO:0007829|PDB:7ZWC" FT HELIX 250..254 FT /evidence="ECO:0007829|PDB:7ZWC" FT STRAND 257..259 FT /evidence="ECO:0007829|PDB:7ZXE" FT HELIX 263..266 FT /evidence="ECO:0007829|PDB:7ZWC" FT TURN 267..270 FT /evidence="ECO:0007829|PDB:7ZWC" FT STRAND 273..275 FT /evidence="ECO:0007829|PDB:7ZWC" FT HELIX 277..286 FT /evidence="ECO:0007829|PDB:7ZWC" FT TURN 289..291 FT /evidence="ECO:0007829|PDB:7XUR" FT HELIX 299..312 FT /evidence="ECO:0007829|PDB:7ZWC" FT HELIX 317..323 FT /evidence="ECO:0007829|PDB:7ZWC" FT HELIX 330..339 FT /evidence="ECO:0007829|PDB:7ZWC" FT STRAND 342..345 FT /evidence="ECO:0007829|PDB:7ZWC" FT HELIX 351..364 FT /evidence="ECO:0007829|PDB:7ZWC" FT HELIX 372..376 FT /evidence="ECO:0007829|PDB:7ZWC" FT STRAND 379..381 FT /evidence="ECO:0007829|PDB:7ZWC" FT HELIX 384..393 FT /evidence="ECO:0007829|PDB:7ZWC" FT STRAND 394..396 FT /evidence="ECO:0007829|PDB:7ZXE" FT STRAND 397..399 FT /evidence="ECO:0007829|PDB:7XUR" FT HELIX 408..411 FT /evidence="ECO:0007829|PDB:8IUH" FT HELIX 414..418 FT /evidence="ECO:0007829|PDB:8IUH" FT HELIX 425..428 FT /evidence="ECO:0007829|PDB:8IUH" FT HELIX 436..447 FT /evidence="ECO:0007829|PDB:8IUH" FT HELIX 460..467 FT /evidence="ECO:0007829|PDB:8IUH" FT STRAND 470..472 FT /evidence="ECO:0007829|PDB:8IUH" FT STRAND 475..477 FT /evidence="ECO:0007829|PDB:8IUH" FT HELIX 478..481 FT /evidence="ECO:0007829|PDB:8IUH" FT STRAND 483..485 FT /evidence="ECO:0007829|PDB:8IUH" FT HELIX 488..501 FT /evidence="ECO:0007829|PDB:8IUH" FT TURN 502..504 FT /evidence="ECO:0007829|PDB:8IUH" FT HELIX 506..509 FT /evidence="ECO:0007829|PDB:8IUH" FT HELIX 510..512 FT /evidence="ECO:0007829|PDB:8IUH" SQ SEQUENCE 1469 AA; 159433 MW; 78CBCFB1887E106C CRC64; MDVDAEREKI TQEIKELERI LDPGSSGSHV EISESSLESD SEADSLPSED LDPADPPISE EERWGEASND EDDPKDKTLP EDPETCLQLN MVYQEVIQEK LAEANLLLAQ NREQQEELMR DLAGSKGTKV KDGKSLPPST YMGHFMKPYF KDKVTGVGPP ANEDTREKAA QGIKAFEELL VTKWKNWEKA LLRKSVVSDR LQRLLQPKLL KLEYLHQKQS KVSSELERQA LEKQGREAEK EIQDINQLPE EALLGNRLDS HDWEKISNIN FEGSRSAEEI RKFWQNSEHP SINKQEWSRE EEERLQAIAA AHGHLEWQKI AEELGTSRSA FQCLQKFQQH NKALKRKEWT EEEDRMLTQL VQEMRVGSHI PYRRIVYYME GRDSMQLIYR WTKSLDPGLK KGYWAPEEDA KLLQAVAKYG EQDWFKIREE VPGRSDAQCR DRYLRRLHFS LKKGRWNLKE EEQLIELIEK YGVGHWAKIA SELPHRSGSQ CLSKWKIMMG KKQGLRRRRR RARHSVRWSS TSSSGSSSGS SGGSSSSSSS SSEEDEPEQA QAGEGDRALL SPQYMVPDMD LWVPARQSTS QPWRGGAGAW LGGPAASLSP PKGSSASQGG SKEASTTAAA PGEETSPVQV PARAHGPVPR SAQASHSADT RPAGAEKQAL EGGRRLLTVP VETVLRVLRA NTAARSCTQK EQLRQPPLPT SSPGVSSGDS VARSHVQWLR HRATQSGQRR WRHALHRRLL NRRLLLAVTP WVGDVVVPCT QASQRPAVVQ TQADGLREQL QQARLASTPV FTLFTQLFHI DTAGCLEVVR ERKALPPRLP QAGARDPPVH LLQASSSAQS TPGHLFPNVP AQEASKSASH KGSRRLASSR VERTLPQASL LASTGPRPKP KTVSELLQEK RLQEARAREA TRGPVVLPSQ LLVSSSVILQ PPLPHTPHGR PAPGPTVLNV PLSGPGAPAA AKPGTSGSWQ EAGTSAKDKR LSTMQALPLA PVFSEAEGTA PAASQAPALG PGQISVSCPE SGLGQSQAPA ASRKQGLPEA PPFLPAAPSP TPLPVQPLSL THIGGPHVAT SVPLPVTWVL TAQGLLPVPV PAVVSLPRPA GTPGPAGLLA TLLPPLTETR AAQGPRAPAL SSSWQPPANM NREPEPSCRT DTPAPPTHAL SQSPAEADGS VAFVPGEAQV AREIPEPRTS SHADPPEAEP PWSGRLPAFG GVIPATEPRG TPGSPSGTQE PRGPLGLEKL PLRQPGPEKG ALDLEKPPLP QPGPEKGALD LGLLSQEGEA ATQQWLGGQR GVRVPLLGSR LPYQPPALCS LRALSGLLLH KKALEHKATS LVVGGEAERP AGALQASLGL VRGQLQDNPA YLLLRARFLA AFTLPALLAT LAPQGVRTTL SVPSRVGSES EDEDLLSELE LADRDGQPGC TTATCPIQGA PDSGKCSASS CLDTSNDPDD LDVLRTRHAR HTRKRRRLV //